Helicobacter pylori infection in Europe: current perspectives

References

• Malfertheiner P, Mégraud F, O'Morain C et al. Current European concepts in the management of Helicobacter pylori infection – the Maastricht Consensus Report. The European Helicobacter pylori Study Group (EHPSG). Eur. J. Gastroenterol. Hepatol. 9(1), 1–2 (1997).
   PubMed Web of Science ®Google Scholar
• Lee J, O'Morain C. Consensus or confusion: a review of existing national guidelines on Helicobacter pylori related disease. Eur. J. Gastroenterol. Hepatol. 9(5), 527–531 (1997).
   PubMedGoogle Scholar
• Pounder RE, Ng D. The prevalence of Helicobacter pylori infection in different countries. Aliment. Pharmacol. Ther. 9(Suppl. 2), 33–39 (1995).
   PubMed Web of Science ®Google Scholar
• Graham DY, Malaty HM, Evans DG, Evans DJ, Klein PD, Adam E. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology 100(6), 1495–1501 (1991).
   PubMed Web of Science ®Google Scholar
• EUROGAST Study Group. Epidemiology of, and risk factors for, Helicobacter pylori infection among 3194 asymptomatic subjects in 17 populations. Gut 34(12), 1672–1676 (1993).
   PubMed Web of Science ®Google Scholar
• Webb PM, Hengels KJ, Møller H et al. The epidemiology of low serum pepsinogen A levels and an international association with gastric cancer rates. EUROGAST Study Group. Gastroenterology 107(5), 1335–1344 (1994).
   PubMed Web of Science ®Google Scholar
• Breckan RK, Paulssen EJ, Asfeldt AM, Mortensen L, Straume B, Florholmen J. The impact of body mass index and Helicobacter pylori infection on gastro-oesophageal reflux symptoms: a population-based study in northern Norway. Scand. J. Gastroenterol. 44(9), 1060–1066 (2009).
   PubMed Web of Science ®Google Scholar
• Jackson L, Britton J, Lewis SA et al. A population-based epidemiologic study of Helicobacter pylori infection and its association with systemic inflammation. Helicobacter 14(5), 108–1013 (2009).
   PubMedGoogle Scholar
• World Health Organisation; International Agency for Research on Cancer. Globocan WHO, Geneva, Swtizerland (2008).
   Google Scholar
• O'Connor A, Taneike I, Nami A et al. Helicobacter pylori resistance to metronidazole and clarithromycin in Ireland. Eur. J. Gastroenterol. Hepatol. 22(9), 1123–1127 (2010).
   PubMedGoogle Scholar
• Arslan E, Atilgan H, Yavas¸og˘lu I. The prevalence of Helicobacter pylori in obese subjects. Eur. J. Intern. Med. 20(7), 695–697 (2009).
   PubMedGoogle Scholar
• Megraud F, Coenen S, Versporten A et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 62(1), 34–42 (2013).
   PubMed Web of Science ®Google Scholar
• Katsanos KH, Tatsioni A, Tsakiris V, Christodoulou D, Tsianos EV. Helicobacter pylori is a major public health priority in western Balkans: an endoscopy referral center experience. Eur. J. Intern. Med. 21(4), 306–309 (2010).
   PubMedGoogle Scholar
• Malfertheiner P, Megraud F, O'Morain CA et al. Management of Helicobacter pylori infection – the Maastricht IV/ Florence Consensus Report. Gut 61(5), 646–664 (2012).
   PubMed Web of Science ®Google Scholar
• Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut 45(Suppl. 2), II37–42 (1999).
   PubMedGoogle Scholar
• Ikenberry SO, Harrison ME, Lichtenstein D et al. ASGE standards of practice committee. The role of endoscopy in dyspepsia. Gastrointest. Endosc. 66(6), 1071–1075 (2007).
   PubMed Web of Science ®Google Scholar
• Talley NJ; American Gastroenterological Association. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology 129(5), 1753–1755 (2005).
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Axon AT. The usefulness of the likelihood ratio in the diagnosis of dyspepsia and gastroesophageal reflux disease. Am. J. Gastroenterol. 94(11), 3122–3125 (1999).
   PubMed Web of Science ®Google Scholar
• Duggan AE, Elliott CA, Miller P et al. Clinical trial: a randomized trial of early endoscopy, Helicobacter pylori testing and empirical therapy for the management of dyspepsia in primary care. Aliment. Pharmacol. Ther. 29(1), 55–68 (2009).
   PubMedGoogle Scholar
• Moayyedi P, Deeks J, Talley NJ et al. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am. J. Gastroenterol. 98(12), 2621–2626 (2003).
   PubMed Web of Science ®Google Scholar
• Apseloff G. Severe neutropenia among healthy volunteers given rifabutin in clinical trials. Clin. Pharmacol. Ther 74, 591–2 (2003).
   PubMedGoogle Scholar
• Hetzel DJ, Dent J, Reed WD et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 95(4), 903–912 (1988).
   PubMed Web of Science ®Google Scholar
• Robinson M, Lanza F, Avner D et al. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 124(10), 859–867 (1996).
   PubMed Web of Science ®Google Scholar
• O’Connor HJ. Helicobacter pylori and gastro-oesophageal reflux disease – clinical implications and management. Aliment. Pharmacol. Ther. 13(2), 117–127 (1999).
   PubMedGoogle Scholar
• Rokkas T, Pistiolas D, Sechopoulos P et al. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin. Gastroenterol. Hepatol. 5(12), 1413–1417, 1417.e1–2 (2007).
   PubMed Web of Science ®Google Scholar
• Corley DA, Kubo A, Levin TR et al. Helicobacter pylori infection and the risk of Barrett's oesophagus: a community-based study. Gut 57(6), 727–733 (2008).
   PubMed Web of Science ®Google Scholar
• Zullo A, Hassan C, Repici A, Annibale B. Intestinal metaplasia surveillance: searching for the road-map. World J. Gastroenterol. 19(10), 1523–1526 (2013).
   PubMed Web of Science ®Google Scholar
• Yaghoobi M, Farrokhyar F, Yuan Y et al. Is there an increased risk of GERD after Helicobacter pylori eradication? A meta-analysis. Am. J. Gastroenterol. 105(5), 1007–1013 (2010).
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Bardhan C, Young L et al. Helicobacter pylori infection and the risk of Barrett's oesophagus: a community-based study. Gastroenterology. 121(5), 1120–1126 (2001).
   PubMed Web of Science ®Google Scholar
• Blower AL, Brooks A, Fenn CG et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment. Pharmacol. Ther. 11, 283–291 (1997).
   PubMed Web of Science ®Google Scholar
• Vergara M, Catalán M, Gisbert JP et al. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment. Pharmacol. Ther. 21(12), 1411–1418 (2005).
   PubMed Web of Science ®Google Scholar
• Chan FK, Chung SC, Suen BY et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N. Engl. J. Med. 344, 967–973 (2001).
   PubMed Web of Science ®Google Scholar
• Lai KC, Lam SK, Chu KM et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N. Engl. J. Med. 346, 2033–2038 (2002).
   PubMed Web of Science ®Google Scholar
• Fletcher EH, Johnston DE, Fisher CR, Koerner RJ, Newton JL, Gray CS. Systematic review: Helicobacter pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin. Aliment. Pharmacol. Ther. 32(7), 831–839 (2010).
   Google Scholar
• Mégraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 53, 1374–1384 (2004).
   PubMed Web of Science ®Google Scholar
• Kearney DJ, Brousal A. Treatment of Helicobacter pylori infection in clinical practice in the United States. Dig. Dis. Sci. 45, 265–271 (2000).
   PubMedGoogle Scholar
• Paoluzi OA, Visconti E, Andrei F et al. Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating Helicobacter pylori infection: a randomized controlled study on efficacy and tolerability. J. Clin. Gastroenterol. 44(4), 261–266 (2010).
   PubMedGoogle Scholar
• Chisholm SA, Teare EL, Davies K et al. Surveillance of primary antibiotic resistance of Helicobacter pylori at centres in England and Wales over a six-year period (2000–2005). Euro Surveill. 12(7), E3–E4 (2007).
   PubMedGoogle Scholar
• Raymond J, Lamarque D, Kalach N et al. High level of antimicrobial resistance in French Helicobacter pylori isolates. Helicobacter 15(1), 21–27 (2010).
   PubMed Web of Science ®Google Scholar
• Megraud F, Coenen S, Versporten A et al. Study Group participants. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 62(1), 34–42 (2013).
   PubMed Web of Science ®Google Scholar
• De Francesco V, Giorgio F, Hassan C et al. Worldwide H. pylori antibiotic resistance: a systematic review. J. Gastrointestin. LiverDis. 19(4), 409–414 (2010).
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Bermejo F, Castro-Fernández M et al. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am. J. Gastroenterol. 103(1), 71–76 (2008).
   PubMed Web of Science ®Google Scholar
• Hung KH, Sheu BS, Chang WL et al. Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan. Helicobacter. 14(1), 61–65 (2009).
   PubMedGoogle Scholar
• van der Linden PD, Sturkenboom MC, Herings RM et al. Fluoroquinolones and risk of Achilles tendon disorders. BMJ 324, 1306–1307 (2002).
   PubMed Web of Science ®Google Scholar
• Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann. Intern. Med. 148(12), 923–931 (2008).
   PubMed Web of Science ®Google Scholar
• Vaira D, Zullo A, Vakil N et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann. Intern. Med. 146(8), 556–563 (2007).
   PubMed Web of Science ®Google Scholar
• Essa AS, Kramer JR, Graham DY et al. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing ‘concomitant therapy’ versus triple therapy for Helicobacter pylori eradication. Helicobacter 14(2), 109–118 (2009).
   PubMed Web of Science ®Google Scholar
• Laine L, Hunt R, El-Zimaity H et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am. J. Gastroenterol. 98(3), 562–567 (2003).
   PubMed Web of Science ®Google Scholar
• O'Morain C, Borody T, Farley A et al. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment. Pharmacol. Ther. 17(3), 415–420 (2003).
   PubMedGoogle Scholar
• Malfertheiner P, Bazzoli F, Delchier JC et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, Phase 3 trial. Lancet 377(9769), 905–913 (2012).
   Google Scholar
• Calvet X, García N, López T et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment. Pharmacol. Ther. 14, 603–609 (2000).
   PubMed Web of Science ®Google Scholar
• Fuccio L, Minardi ME, Zagari RM et al. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann. Int. Med. 147, 553–562 (2007).
   PubMed Web of Science ®Google Scholar
• O'Connor JP, Taneike I, O'Morain C. Improving compliance with Helicobacter pylori eradication therapy: when and how? Therap. Adv. Gastroenterol. 2(5), 273–279 (2009).
   PubMedGoogle Scholar
• Correa P, Haenszel W, Cuello C et al. A model for gastric cancer epidemiology. Lancet 2(7924), 58–60 (1975).
   PubMed Web of Science ®Google Scholar
• Rugge M, Meggio A, Pennelli G et al. Gastritis staging in clinical practice: the OLGA staging system. Gut 56(5), 631–636 (2007).
   PubMed Web of Science ®Google Scholar
• Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 18(3), 581–592 (2007).
   PubMed Web of Science ®Google Scholar
• National Cancer Registry. Cancer Projections 2005–2035. National Cancer Registry, Cork, Ireland (2008).
   Google Scholar
• Fuccio L, Zagari RM, Eusebi LH et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann. Intern. Med. 151(2), 121–128 (2009).
   PubMed Web of Science ®Google Scholar
• Roderick P, Davies R, Raftery J et al. Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation. J. Med. Screen 10(3), 148–156 (2003).
   PubMed Web of Science ®Google Scholar
• de Vries AC, Meijer GA, Looman CW et al. Epidemiological trends of pre-malignant gastric lesions: a long-term nationwide study in The Netherlands. Gut 56(12), 1665–1670 (2007).
   PubMed Web of Science ®Google Scholar
• El-Omar EM, Oien K, Murray LS et al. Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori. Gastroenterology 118(1), 22–30 (2000).
   PubMed Web of Science ®Google Scholar
• El-Omar EM, Carrington M, Chow WH et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404(6776), 398–402 (2000).
   PubMed Web of Science ®Google Scholar
• Franceschi F, Leo D, Fini L et al. Helicobacter pylori infection and ischaemic heart disease: an overview of the general literature. Dig. Liver Dis. 37(5), 301–308 (2005).
   PubMedGoogle Scholar
• Sempértegui F, Díaz M, Mejía R et al. Low concentrations of zinc in gastric mucosa are associated with increased severity of Helicobacter pylori-induced inflammation. Helicobacter. 12(1), 43–48 (2007).
   PubMed Web of Science ®Google Scholar
• Arnold DM, Bernotas A, Nazi I et al. Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review. Haematologica 94(6), 850–856 (2009).
   PubMed Web of Science ®Google Scholar
• Yuan W, Yumin L, Kehu Y et al. Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials. Scand. J. Gastroenterol. 45(6), 665–676 (2010).
   PubMed Web of Science ®Google Scholar
• Chen Y, Blaser MJ. Inverse associations of Helicobacter pylori with asthma and allergy. Arch. Intern. Med. 167(8), 821–827 (2007).
   PubMedGoogle Scholar
• Fullerton D, Britton JR, Lewis SA. Helicobacter pylori and lung function, asthma, atopy and allergic disease – a population-based cross-sectional study in adults. Int. J. Epidemiol. 38(2), 419–426 (2009).
   PubMed Web of Science ®Google Scholar
• Kawashima J, Ohno S, Sakurada T et al. Circulating acylated ghrelin level decreases in accordance with the extent of atrophic gastritis. J. Gastroenterol. 44(10), 1046–1054 (2009).
   PubMed Web of Science ®Google Scholar
• Ioannou GN, Weiss NS, Kearney DJ. Is Helicobacter pylori seropositivity related to body mass index in the United States? Aliment. Pharmacol. Ther. 21(6), 765–772 (2005).
   PubMedGoogle Scholar
• Figura N, Franceschi F, Santucci A et al. Extragastric manifestations of Helicobacter pylori infection. Helicobacter 15(Suppl. 1), 60–68 (2010).
   PubMed Web of Science ®Google Scholar
• Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 338, 1175–1176 (1991).
   PubMed Web of Science ®Google Scholar
• Parsonnet J, Hansen S, Rodriguez L et al. Helicobacter pylori infection and gastric lymphoma. N. Engl. J. Med. 330, 1267–1271 (1994).
   PubMed Web of Science ®Google Scholar
• Eck M, Schmausser B, Greiner A, Müller-Hermelink HK. Helicobacter pylori in gastric mucosa-associated lymphoid tissue type lymphoma. Recent Results Cancer Res. 156, 9–18 (2000).
   PubMedGoogle Scholar
• Nakamura S, Sugiyama T, Matsumoto T et al. JAPAN GAST Study Group. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut 61(4), 507–513 (2012).
   PubMed Web of Science ®Google Scholar
• Wotherspoon AC, Doglioni C, Diss TC et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342(8871), 575–577 (1993).
   PubMed Web of Science ®Google Scholar
• Yeh KH, Kuo SH, Chen LT et al. Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21). Blood 106(3), 1037 (2005).
   PubMed Web of Science ®Google Scholar
• Dinis-Ribeiro M, Areia M, de Vries AC et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 44(1), 74–94 (2012).
   PubMed Web of Science ®Google Scholar
• Zullo A, Hassan C, Repici A, Bruzzese V. Helicobacter pylori eradication and reflux disease onset: did gastric acid get ‘crazy’? World J. Gastroenterol. 19(6), 786–789 (2013).
   PubMedGoogle Scholar